Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

565
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
565
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.0K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Air-entraining Agents01:27

Air-entraining Agents

272
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
272
Acute Pharyngitis01:30

Acute Pharyngitis

4.2K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
4.2K
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.6K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Leukemia·2026
Same author

APL-like subset within <i>NPM1</i>-mutated AML: A distinct immunophenotype correlating with early vascular complications.

HemaSphere·2026
Same author

A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.

Cancers·2026
Same author

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Blood cancer journal·2026
Same author

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Blood advances·2026
Same author

Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients.

Cancers·2026

Related Experiment Video

Updated: Feb 2, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K

Novel Agents for Acute Myeloid Leukemia.

Mario Luppi1, Francesco Fabbiano2, Giuseppe Visani3

  • 1Section of Hematology Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena Università di Modena e Reggio Emilia, 41125 Modena, Italy. mario.luppi@unimore.it.

Cancers
|November 15, 2018
PubMed
Summary

New targeted therapies and agents are emerging for acute myeloid leukemia (AML) treatment, offering alternatives beyond the standard "3 + 7" regimen for adult patients. These advancements include novel drugs and formulations showing promising results in clinical investigations.

Keywords:
CPX-351FLT3acute myeloid leukemiaenasidenibgemtuzumab ozogamicinmidostaurinpalliative care“7 + 3” regimen

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K

Related Experiment Videos

Last Updated: Feb 2, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) presents significant heterogeneity, driving the need for advanced treatment strategies.
  • The current standard of care for AML, the "3 + 7" regimen, is being challenged by emerging targeted therapies.
  • Understanding AML pathogenesis has led to the development of novel agents with specific molecular targets.

Purpose of the Study:

  • To review recently approved and investigational drugs for adult acute myeloid leukemia (AML).
  • To describe novel therapeutic options including targeted therapies, monoclonal antibodies, and novel formulations.
  • To present promising results of emerging AML treatments as monotherapy or in combination regimens.

Main Methods:

  • Review of recently approved drugs for AML treatment.
  • Description of novel agents currently under investigation for AML.
  • Analysis of promising monotherapy and combination therapy results for emerging AML treatments.

Main Results:

  • Recently approved AML therapies include targeted agents (midostaurin, enasidenib), monoclonal antibodies (gemtuzumab ozogamicin), and a liposomal formulation (CPX-351).
  • Investigational agents show promising results, both as single agents and in combination with chemotherapy.
  • These new options aim to improve outcomes for adult patients with acute myeloid leukemia.

Conclusions:

  • Recent advancements offer new therapeutic avenues for acute myeloid leukemia (AML) beyond traditional chemotherapy.
  • Emerging targeted therapies and novel drug formulations represent a significant step forward in AML treatment.
  • Further investigation into these novel agents is crucial for optimizing AML patient care.